Technical Analysis for LQDA - Liquidia Technologies, Inc.

Grade Last Price % Change Price Change
grade C 20.51 -3.98% -0.85
LQDA closed down 3.98 percent on Monday, December 17, 2018, on 42 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical LQDA trend table...

Date Alert Name Type % Chg
Dec 17 20 DMA Resistance Bearish 0.00%
Dec 17 MACD Bearish Centerline Cross Bearish 0.00%
Dec 17 Spinning Top Other 0.00%
Dec 17 Multiple of Ten Bullish Other 0.00%
Dec 17 Outside Day Range Expansion 0.00%
Dec 17 Down 3 Days in a Row Weakness 0.00%
Dec 17 Down 4 Days in a Row Weakness 0.00%
Dec 17 Down 5 Days in a Row Weakness 0.00%
Dec 14 20 DMA Resistance Bearish -3.98%
Dec 14 MACD Bearish Signal Line Cross Bearish -3.98%

Older signals for LQDA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Is LQDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 38.46
52 Week Low 10.52
Average Volume 39,128
200-Day Moving Average 0.0
50-Day Moving Average 22.9052
20-Day Moving Average 21.751
10-Day Moving Average 22.104
Average True Range 2.3976
ADX 11.67
+DI 20.4984
-DI 21.9304
Chandelier Exit (Long, 3 ATRs ) 19.1372
Chandelier Exit (Short, 3 ATRs ) 25.2228
Upper Bollinger Band 24.2077
Lower Bollinger Band 19.2943
Percent B (%b) 0.25
BandWidth 22.589306
MACD Line -0.0648
MACD Signal Line 0.043
MACD Histogram -0.1078
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.76
Resistance 3 (R3) 24.93 23.68 24.05
Resistance 2 (R2) 23.68 22.60 23.60 23.81
Resistance 1 (R1) 22.10 21.93 21.48 21.93 23.58
Pivot Point 20.85 20.85 20.54 20.77 20.85
Support 1 (S1) 19.27 19.77 18.65 19.10 17.44
Support 2 (S2) 18.02 19.10 17.94 17.21
Support 3 (S3) 16.44 18.02 16.97
Support 4 (S4) 16.27